TY - JOUR
T1 - Fentanyl and fentanyl analogs in the illicit stimulant supply
T2 - Results from U.S. drug seizure data, 2011–2016
AU - Park, Ju Nyeong
AU - Rashidi, Emaan
AU - Foti, Kathryn
AU - Zoorob, Michael
AU - Sherman, Susan
AU - Alexander, G. Caleb
N1 - Funding Information:
Dr. Park has served as a consultant to the Maryland Opioid Operational Command Center and the Delaware Department of Health and Social Services through funding from the Bloomberg American Health Initiative. Dr. Sherman is an expert witness for plaintiffs in opioid litigation. Dr. Alexander is past Chair of FDA’s Peripheral and Central Nervous System Advisory Committee; has served as a paid advisor to IQVIA; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. ER, KF and MZ have no disclosures to declare.
Funding Information:
Dr. Park is supported in part by a Faculty Development Award from the Johns Hopkins University Center for AIDS Research ( 1P30AI094189 ). Michael acknowledges support from the James M. and Cathleen D. Stone PhD Scholarship in Inequality and Wealth Concentration.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Background: U.S. research examining the illicit drug supply remains rare even though the information could help reduce overdoses. Relatively little is known regarding how often opioids are found in stimulants and whether temporal and geographic trends exist. We examined trends in fentanyl-cocaine and fentanyl-methamphetamine combinations in the national illicit drug supply. Methods: We analysed serial cross-sectional data from the National Forensic Laboratory Information System (NFLIS) collected between January 2011 and December 2016. We restricted the analysis to cocaine (N = 1,389,968) and methamphetamine (n = 1,407,474) samples and calculated proportions containing fentanyl (including 23 related analogs) over time. Results: The combined presence of fentanyl and cocaine steadily increased nationally between 2012–2016 (p = 0.01), and the number of such samples tripled from 2015 to 2016 (n = 423 to n = 1,325). Similarly, the combined presence of fentanyl and methamphetamine increased 179 % from 2015 to 2016 (n = 82–n = 272). Patterns varied widely by state; in 2016, fentanyl-cocaine samples were most common in New Hampshire (7.2 %), Connecticut (5.4 %), Ohio (2.6 %) and Massachusetts (2.1 %), whereas fentanyl-methamphetamine samples were most often in New Hampshire (6.1 %), Massachusetts (5.6 %), Vermont (2.4 %) and Maine (1.2 %). Conclusions: Although relatively uncommon, the presence of fentanyl in the stimulant supply increased significantly between 2011 and 2016, with the greatest increases occuring between 2015–2016; the presence of these products was concentrated in the U.S. Northeast. Given these trends, strengthening community-based drug checking programs and surveillance within the public health infrastructure could help promote timely responses to novel threats posed by rapid shifts in the drug supply that may lead to inadvertent exposures.
AB - Background: U.S. research examining the illicit drug supply remains rare even though the information could help reduce overdoses. Relatively little is known regarding how often opioids are found in stimulants and whether temporal and geographic trends exist. We examined trends in fentanyl-cocaine and fentanyl-methamphetamine combinations in the national illicit drug supply. Methods: We analysed serial cross-sectional data from the National Forensic Laboratory Information System (NFLIS) collected between January 2011 and December 2016. We restricted the analysis to cocaine (N = 1,389,968) and methamphetamine (n = 1,407,474) samples and calculated proportions containing fentanyl (including 23 related analogs) over time. Results: The combined presence of fentanyl and cocaine steadily increased nationally between 2012–2016 (p = 0.01), and the number of such samples tripled from 2015 to 2016 (n = 423 to n = 1,325). Similarly, the combined presence of fentanyl and methamphetamine increased 179 % from 2015 to 2016 (n = 82–n = 272). Patterns varied widely by state; in 2016, fentanyl-cocaine samples were most common in New Hampshire (7.2 %), Connecticut (5.4 %), Ohio (2.6 %) and Massachusetts (2.1 %), whereas fentanyl-methamphetamine samples were most often in New Hampshire (6.1 %), Massachusetts (5.6 %), Vermont (2.4 %) and Maine (1.2 %). Conclusions: Although relatively uncommon, the presence of fentanyl in the stimulant supply increased significantly between 2011 and 2016, with the greatest increases occuring between 2015–2016; the presence of these products was concentrated in the U.S. Northeast. Given these trends, strengthening community-based drug checking programs and surveillance within the public health infrastructure could help promote timely responses to novel threats posed by rapid shifts in the drug supply that may lead to inadvertent exposures.
KW - Fentanyl
KW - Opioids
KW - Overdose
KW - Stimulants
KW - Substance use
UR - http://www.scopus.com/inward/record.url?scp=85097000736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097000736&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2020.108416
DO - 10.1016/j.drugalcdep.2020.108416
M3 - Article
C2 - 33278761
AN - SCOPUS:85097000736
VL - 218
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
SN - 0376-8716
M1 - 108416
ER -